Marina Biotech Inc (NASDAQOTH:MRNA)

CAPS Rating: 2 out of 5

A pharmaceutical company, which is focusing on development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology for delivering both small and large molecule drugs.

Results 1 - 20 of 31 : 1 2 Next »

Recs

2
Member Avatar zzlangerhans (99.85) Submitted: 3/1/2014 11:16:46 AM : Outperform Start Price: $1.04 MRNA Score: -27.89

I had Marina on the far far backburner in December, given that the company appeared to be insolvent with a share price on the path to 0 and was not compliant with their financial statements. Furthermore, they had gone completely silent in the PR department, an area in which they used to be quite prolific. Just as I was writing them off for good, Portefeuille was becoming more interested in them based on his own sources. I countered his initial suggestion that I buy shares with the argument that there was no evidence that the company continued to exist in any meaningful way. I attempted to contact Marina IR by phone and e-mail to inquire about whether they were continuing to conduct any meaningful operations, and as I expected, I received no answer. Nevertheless, Portefeuille continued to encourage initiating a position. Since my previous resistances have always led to loss of potential gains for the zzporte portfolio, I agreed to some small purchases and we now have 4000 shares with cost basis of 0.79. Portefeuille initially began talking about Marina at about 0.25, we made our first purchase at 0.46, and the share price recently hit 1.71 before pulling back in the later part of this week. Since I have no clue what is driving the resurgence in the stock, aside from some new PR about patents, I won't be closing this pick until we have closed most of our real life position in the stock.

Recs

0
Member Avatar loangolfer (< 20) Submitted: 2/13/2014 8:58:14 AM : Outperform Start Price: $0.94 MRNA Score: -17.26

just like real estate bio,bio,bio!

Recs

0
Member Avatar KINGDEEDEE (< 20) Submitted: 3/16/2011 9:30:23 AM : Outperform Start Price: $6.20 MRNA Score: -146.95

Lots of Value, and it will be in full growth as it sells more shares raising value for the company!

Recs

0
Member Avatar jukns (< 20) Submitted: 3/14/2011 1:30:36 PM : Outperform Start Price: $6.56 MRNA Score: -146.29

They are work with Novartis! Just because of this, they are set for the loung-haul.

Recs

2
Member Avatar JDSancho (99.51) Submitted: 6/18/2008 9:26:57 PM : Underperform Start Price: $251.60 MRNA Score: +149.15

This Minyanville article sums up my feelings on MDRNA...I mean...Nastech...no, I was right, MDRwhocares.

http://www.minyanville.com/articles/MRK-amgn-IMCL-CTIC-ALNY-MRNA/index/a/17562/from/yahoo

This company plays perfectly into my "underperform due to sudden name change but not sudden better business outlook" theory. Truth be told, I did not read the whole article for I find biotech information rather boring and completely un-understandable. But, I read enough to make an underperform call here...said company lacks patents (and cash for that matter, only $20M left). I know enough to understand that patents (and cash) are everything in this field. When MDRNA secures a patent, it will be time to bail on this red thumb, but that doesn't look likely, at least any time soon. Plus, they have all kinds of management problems, which usually does not lead to a higher stock price. Therefore, I'll wait for my bankruptcy charm.

Recs

0
Member Avatar MyMacFool (69.27) Submitted: 11/14/2007 2:47:43 PM : Underperform Start Price: $231.40 MRNA Score: +145.76

GREAT IDEAS CRAPPY PERFORMANCE

Recs

0
Member Avatar pgueudet (< 20) Submitted: 11/9/2007 10:52:02 AM : Underperform Start Price: $254.00 MRNA Score: +148.68

No product on the market, No partner

Recs

0
Member Avatar jpmkorea (< 20) Submitted: 11/7/2007 11:37:33 AM : Outperform Start Price: $356.40 MRNA Score: -144.10

Contrarian strategy to the max. Buy Low, Sell High. Oh Yeah!

Recs

0
Member Avatar SanDieguito (< 20) Submitted: 11/7/2007 9:34:44 AM : Underperform Start Price: $386.80 MRNA Score: +143.78

down $4 to $10

Recs

0
Member Avatar DrQuay (< 20) Submitted: 9/28/2007 9:04:17 AM : Underperform Start Price: $532.00 MRNA Score: +141.87

9/28/07 Ingredients for Failure!
1)Past record and continued loses makes statistics dismal.
2)After 32 Touts & Video's by Jim Cramer all year, he has now stated on his show 9/26 That Nstk is Don't Buy and wait until it's around $12 dollars.
3) Areas of Osteoporosis, Diabetes, and RNAI are suspect to be successful.
4) September was a record for the most insider sales all year.
5) Year End Earnings Report in March 2008 should create New Lows.
6) After 5 consecutive years stock price is not steady and about the same.

Recs

0
Member Avatar tharlow (72.66) Submitted: 8/13/2007 11:27:49 PM : Outperform Start Price: $575.20 MRNA Score: -149.56

Massive upside.

Recs

0
Member Avatar wisedrdave (28.94) Submitted: 7/30/2007 6:08:56 AM : Outperform Start Price: $504.80 MRNA Score: -149.29

Biopharm company that actually has recent patents instead of multiple "phase III trial" experiments. Nose spray for osteoporosis and obesity. potential if marketed and received well.

Recs

0
Member Avatar cohicks (47.73) Submitted: 7/19/2007 9:04:54 PM : Outperform Start Price: $513.20 MRNA Score: -140.65

This has the potential to explode if one of their products makes it. Good spec play.

Recs

0
Member Avatar snielsen2 (42.62) Submitted: 6/4/2007 6:37:45 PM : Outperform Start Price: $474.40 MRNA Score: -142.31

$79mm in cash and $12mm in debt, this company has capital to continue to market and grow. The company has agreements with Procter & Gamble Pharmaceuticals, Inc.; Par Pharmaceutical Companies, Inc.; Merck & Co., Inc.; Amylin Pharmaceuticals, Inc.; Alnylam Pharmaceuticals, Inc.; Galenea Corporation; and Beckman Research Institute/City of Hope. The company copleted its initial phase of its insulin nasal spray, received good results from its carbetocin nasal spray and is working on treatments of autism symptoms. This is a great growth opportunity stock and will be a takeover target .

Recs

0
Member Avatar slick322 (42.17) Submitted: 5/29/2007 10:35:53 AM : Outperform Start Price: $486.40 MRNA Score: -143.78

ok

Recs

0
Member Avatar CheyenneChris (58.29) Submitted: 5/17/2007 10:41:29 PM : Outperform Start Price: $466.40 MRNA Score: -143.92

Earnings soon enough? Promising pipeline!

Recs

0
Member Avatar marymag (< 20) Submitted: 4/20/2007 4:19:06 PM : Outperform Start Price: $564.80 MRNA Score: -147.49

great potential for experimental drugs in pipeline

Recs

0
Member Avatar jordanbh (< 20) Submitted: 4/20/2007 8:58:31 AM : Outperform Start Price: $537.60 MRNA Score: -147.63

long term i dunno, but I like the chart for a trade, high volume buying days, support at the 200 DMA (approx. 11.42), and the cramer hype should make me a percent or two

Recs

0
Member Avatar 0l0l (40.71) Submitted: 4/17/2007 10:52:50 PM : Outperform Start Price: $480.00 MRNA Score: -149.25

Has some bounce left.

Recs

0
Member Avatar micon02 (< 20) Submitted: 4/15/2007 9:56:24 PM : Outperform Start Price: $492.00 MRNA Score: -150.04

Recovery on the upside

Results 1 - 20 of 31 : 1 2 Next »

Featured Broker Partners


Advertisement